PRNewsWire
13 Jul 2026, 08:40 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
ADMA Biologics is facing a securities class action lawsuit alleging the company 'stuffed the channel' to simulate sales activity. — Allegations of artificial revenue inflation via channel stuffing are severe and typically lead to significant stock price declines and loss of investor trust.
-0.70The lawsuit claims ADMA Biologics failed to disclose a related party transaction and made materially misleading public statements. — Lack of transparency regarding related party transactions suggests governance failures and potential conflicts of interest.
-0.50The class period for the alleged securities violations spans from August 9, 2024, to March 25, 2026. — Defines the scope of the liability and the window of time during which the financial data may be unreliable.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
The company is mentioned as being sued for securities law violations in a class action lawsuit.
The company is facing a class action lawsuit alleging securities law violations, false statements, and channel stuffing.
The company is mentioned as being sued for securities law violations in a class action lawsuit.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
1h ago
